microRNA-205 represses breast cancer metastasis by perturbing the rab coupling protein [RCP]-mediated integrin ß1 recycling on the membrane.

During cancer cell invasion, integrin undergoes constant endo/exocytic trafficking. It has been found that the recycling ability of integrin ß1 through Rab11-controlled long loop pathways is directly associated with cancer invasion. Previous studies showed that gain-of-function mutant p53 regulates the Rab-coupling protein [RCP]-mediated integrin ß1 recycling by inactivating tumor suppressor TAp63. So, we were interested to investigate the involvement of miR-205 in this process. In the current study first, we evaluated that the lower expression of miR-205 in MDA-MB-231 cell line is associated with high motility and invasiveness. Further investigation corroborated that miR-205 directly targets RCP resulting in attenuated RCP-mediated integrin ß1 recycling. Overexpression of TAp63 validates our in vitro findings. To appraise the anti-metastatic role of miR-205, we developed two in vivo experimental models- xenograft-chick embryo and xenograft-immunosuppressed BALB/c mice. Our in vivo results support the negative effect of miR-205 on metastasis. Therefore, these findings advocate the tumor suppressor activity of miR-205 in breast cancer cells and suggest that in the future development of miR-205-targeting RNAi therapeutics could be a smart alternative approach to prevent the metastatic fate of the disease.

Discrete Platinum(II/IV)-Arsenito Clusters with Pt-As and Pt-O Bonding: [PtIV(As3O6)2]2-, [Pt4II(H2AsO3)6(HAsO3)2]2-, and [Pt2IIAs6W4O28]10.

The first two discrete, fully inorganic platinum(II/IV)-arsenito clusters, [fac-PtIV(As3O6)2]2- (PtAs6) and [Pt4II(H2AsO3)6(HAsO3)2]2- (Pt4As8), as well as the platinum(II)-arsenito heteropolytungstate [Pt2IIAs6W4O28]10- (Pt2As6W4), have been synthesized in aqueous media using simple one-pot reaction conditions. In PtAs6, a PtIV ion is coordinated to two cyclic, tridentate As3O6 units via oxo-donation (PtIV-O ∼ 2.02 Å). In Pt4As8, each PtII ion is coordinated to four AsO3 ligands via two oxygens and two AsIII atoms in a square-planar fashion (PtII-AsIII 2.31 Å, PtII-O 2.07 Å), resulting in an open cage-like structure, which forms a strong tetrameric assembly in the solid state mediated by two K+ counterions. In Pt2As6W4, each PtII ion is coordinated by the As atoms of three AsO3 ligands (PtII-AsIII 2.38 Å) and an oxo group (PtII-O 2.07 Å) in addition to bridging two tungsten ions, and this polyanion was characterized in solution by 195Pt NMR.

PtIV-Containing Hexaplatinate(II) [PtIVPtII6O6(AsO2(CH3)2)6]2- and Hexapalladate(II) [PtIVPdII6O6(AsO2(CH3)2)6]2.

The first PtIV-containing discrete polyoxoplatinate(II) [PtIVPtII6O6(AsO2(CH3)2)6]2- (Pt7) and polyoxopalladate(II) [PtIVPdII6O6(AsO2(CH3)2)6]2- (PtPd6) have been prepared and characterized in the solid state, in solution, and in the gas phase. The molecular structures of the noble metal-oxo clusters Pt7 and PtPd6 comprise a central, octahedral PtIVO6 hetero group surrounded by six square-planar MO4 (M = PtII, PdII) units, which are capped by six dimethylarsinate ligands. The polyanions were prepared under simple one-pot aqueous solution conditions by reacting H2Pt(OH)6 with either K2PtCl4 or Pd(NO3)2 in sodium dimethylarsinate buffer (pH 7) at 80 °C. Catalytic studies were performed on Pt7 supported on SBA15-apts for o-xylene hydrogenation at 300 °C and 90 bar H2 pressure and indicated excellent activity and recyclability with low activation temperature.

Multistep Cascade Catalytic Reactions Employing Bifunctional Framework Compounds.

Multistep cascade reactions are important to achieve atom as well as step economy over conventional synthesis. This approach, however, is limited due to the incompatibility of the available reactive centers in a catalyst. In the present study, new MOF compounds, [Zn2(SDBA)(3-ATZ)2]·solvent, I and II, with tetrahedral Zn centers as good Lewis acidic sites and the free amino group of the 3-amino triazole ligand as a strong Lewis base center were shown to perform 4-step cascade/tandem reaction in a facile manner. Effective conversion of benzaldehyde dimethyl acetal in the presence of excess nitromethane at 100 °C in water to 1-(1,3-dinitropropan-2-yl) benzene was achieved in 10 h with yields of ∼95% (I) and ∼94% (II). This 4-step cascade reaction proceeds via deacetalization (Lewis acid), Henry (Lewis base), and Michael (Lewis base) reactions. The present work highlights the importance of spatially separated functional groups in multistep tandem catalysis─the examples of which are not common.

Mixed noble metal-oxo clusters: platinum(IV)-gold(III) oxoanion [PtIV2AuIII3O6((CH3)2AsO2)6].

The first discrete mixed platinum(IV)-gold(III) oxoanion [PtIV2AuIII3O6((CH3)2AsO2)6]- (1) was synthesized by reaction of H2Pt(OH)6 with H[AuCl4] in a simple one-pot procedure in aqueous solution at pH 7 and comprises two equivalent PtIVO6(As(CH3)2)3 units which are linked by three square-planar AuIIIO4 units. Polyanion 1 could be isolated as a potassium or sodium salt in good yield, which were structurally characterized in the solid state by single-crystal XRD and TGA, and in solution by multinuclear (1H, 13C, 195Pt) NMR, indicating that polyanion 1 is stable in solution, which was confirmed by ESI-MS studies. The sodium salt of 1 undergoes a clean single-crystal-to-single-crystal (SCSC) structural transformation upon rehydration and dehydration.

Mixed-valent palladium(IV/II)-oxoanion, [PdIVO6PdII6((CH3)2AsO2)6]2.

We report on the first example of a PdIV-containing polyoxopalladate(II). The discrete mixed-valent polyoxopalladate(IV/II), [PdIVPdII6O6((CH3)2AsO2)6]2-, comprising a central PdIV ion that is surrounded by a six-membered PdII-oxo ring capped by six dimethylarsinate groups, was synthesized and structurally characterized in the solid state, in solution and in the gas phase by multiple analytical techniques.

Discrete Arsonate-Grafted Inverted-Keggin 12-Molybdate Ion [Mo12O32(OH)2(4-N3C2H2-C6H4AsO3)4]2- and Formation of a Copper(II)-Mediated Metal-Organic Framework.

The discrete inverted-Keggin ion [Mo12O32(OH)2(4-N3C2H2-C6H4AsO3)4]2- (1) has been prepared in an aqueous acidic (pH 0.8) medium by the reaction of MoO3 with the (4-triazolylphenyl)arsonic acid 4-N3C2H2-C6H4AsO3H2 under hydrothermal conditions and was isolated as a sodium salt in 21% yield. The exact same reaction in the presence of Cu2+ ions resulted in the neutral metal-organic framework (MOF) Cu2[Mo12O34(4-N3C2H2-C6H4AsO3)4] (Cu-1) in 68% yield. The inverted-Keggin ion 1 comprises a metal-oxo core, which is capped by four organoarsonate groups, and in Cu-1, individual polyanions are linked in the solid state by coordination of the Cu2+ ions with the triazolyl groups. The discrete ion 1 was characterized by single-crystal X-ray diffraction (XRD), Fourier transform infrared (FT-IR), and atomic absorption (AA) spectroscopy, as well as thermogravimetric analysis (TGA), and the POM-MOF Cu-1 was characterized by single-crystal and powder XRD, FT-IR, TGA, and gas sorption. Cu-1 has channels with a diameter of around ∼0.9 nm and exhibits a water-vapor adsorption capacity of 89.7 cm3 g-1 (p/p0 = 0.95).

Organically Functionalized Mixed-Valent Polyoxo-30-molybdate Wheel and Neutral Tetramolybdenum(V) Oxo Cluster.

The first organofunctionalized mixed-valent polyoxo-30-molybdate wheel, [MoVI18MoV12O84{AsO2(CH3)2}18]18- (Mo30), was synthesized in aqueous, mildly acidic conditions, and upon further acidification, the neutral tetramolybdenum(V) oxo cluster [MoV4O8{AsO2(CH3)2}4] (Mo4) was obtained. Single-crystal X-ray diffraction (XRD) revealed that Mo30 comprises 18 MoVI and 12 MoV ions arranged in a cyclic fashion with alternating {MoV2} and {MoVI3} groups, which are capped by 18 dimethylarsinate ligands, resulting in a novel polyoxo-30-molybdate wheel with a central cavity of ∼1.5 nm. On the other hand, Mo4 has a distorted-cubic structure, with the corners of the cube being occupied by alternating MoV ions and oxo ligands. The compounds were characterized in solution by 1H and 13C NMR and UV-vis spectroscopy and in the solid state by X-ray photoelectron spectroscopy and powder XRD. Mo30 represents a novel type of polyanionic cycle with manyfold possibilities regarding host-guest chemistry.

Discovery of Polythioplatinate(II) [Pt3S2(SO3)6]10- and Study of Its Solution and Catalytic Properties.

We have discovered the first polythioplatinate(II), [PtII3S2(SO3)6]10- (1), which was synthesized in aqueous basic medium (pH 11) by hydrothermal heating at 150 °C. Polyanion 1 comprises a discrete, triangular assembly of three Pt2+ ions linked by two µ3-sulfido ligands, and their square-planar coordination geometry is completed by two terminal S-bound sulfito ligands. Polyanion 1 was isolated as a hydrated sodium salt, Na10[PtII3(µ3-S)2(SO3)6]·22H2O (Na-1), which was characterized in the solid state by single-crystal X-ray diffraction, Fourier-transform infrared spectroscopy, thermogravimetric analysis, X-ray photoelectron spectra, and elemental analysis, in solution by 195Pt NMR and atomic absorption spectroscopy, and in the gas phase by electrospray ionization mass spectrometry. Density functional theory calculations were performed, and the 195Pt NMR chemical shifts of 1 were computed theoretically and shown to match well with the experimental data. Furthermore, the discrete title polyanion 1 was immobilized on mesoporous SBA-15 support and used as a precatalyst for the hydrogenation of o-xylene.

Discrete, Cationic Palladium(II)-Oxo Clusters via f-Metal Ion Incorporation and their Macrocyclic Host-Guest Interactions with Sulfonatocalixarenes.

We report on the discovery of the first two examples of cationic palladium(II)-oxo clusters (POCs) containing f-metal ions, [PdII6 O12 M8 {(CH3 )2 AsO2 }16 (H2 O)8 ]4+ (M=CeIV , ThIV ), and their physicochemical characterization in the solid state, in solution and in the gas phase. The molecular structure of the two novel POCs comprises an octahedral {Pd6 O12 }12- core that is capped by eight MIV ions, resulting in a cationic, cubic assembly {Pd6 O12 MIV8 }20+ , which is coordinated by a total of 16 terminal dimethylarsinate and eight water ligands, resulting in the mixed PdII -CeIV /ThIV oxo-clusters [PdII6 O12 M8 {(CH3 )2 AsO2 }16 (H2 O)8 ]4+ (M=Ce, Pd6 Ce8 ; Th, Pd6 Th8 ). We have also studied the formation of host-guest inclusion complexes of Pd6 Ce8 and Pd6 Th8 with anionic 4-sulfocalix[n]arenes (n=4, 6, 8), resulting in the first examples of discrete, enthalpically-driven supramolecular assemblies between large metal-oxo clusters and calixarene-based macrocycles. The POCs were also found to be useful as pre-catalysts for electrocatalytic CO2 -reduction and HCOOH-oxidation.

MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma.

The degree of metastatic disease varies widely among patients with cancer and affects clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multifluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC)-a tumor type in which most patients present with metastases. Genomic and transcriptomic analysis revealed an association between metastatic burden and gene amplification or transcriptional upregulation of MYC and its downstream targets. Functional experiments showed that MYC promotes metastasis by recruiting tumor-associated macrophages, leading to greater bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically in metastatic patients. Collectively, these results implicate MYC activity as a major determinant of metastatic burden in advanced PDAC. SIGNIFICANCE: Here, we investigate metastatic variation seen clinically in patients with PDAC and murine PDAC tumors and identify MYC as a major driver of this heterogeneity.This article is highlighted in the In This Issue feature, p. 275.

Organorhodium(III)- and Iridium(III)-Substituted 20-Tungstobismuthates(III) and -Antimonates(III), [(MCp*)2X2W20O70]10- (M = RhIII and IrIII; X = BiIII and SbIII).

The synthesis of four organometallic RhCp*- and IrCp*-containing heteropoly-20-tungstates, [{RhCp*}2Bi2W20O70]10- (1), [{IrCp*}2Bi2W20O70]10- (2), [{RhCp*}2Sb2W20O70]10- (3), and [{IrCp*}2Sb2W20O70]10- (4) has been accomplished by reaction of (MCp*Cl2)2 with [X2W22O74(OH)2]12- in aqueous solution at pH 6 and 70 °C. The four polyanions 1-4 were structurally characterized in the solid state by single-crystal XRD, FTIR, and TGA and in solution by 183W and 13C NMR. For the Rh derivatives 1 and 3 the 183W-103Rh coupling (2 J W-Rh 3.0 Hz) could be identified by 183W NMR.

Delivery of gefitinib in synergism with thymoquinone via transferrin-conjugated nanoparticle sensitizes gefitinib-resistant non-small cell lung carcinoma to control metastasis and stemness.

Epidermal growth factor receptor (EGFR) normally over-expresses in non-small cell lung cancer (NSCLC) cells. Its mutations act as oncogenic drivers in the cellular signal transduction pathway, and induce the downstream activation of numerous key cellular events involved in cellular proliferation and survival. EGFR tyrosine kinase inhibitors (EGFR-TK inhibitors), such as gefitinib and erlotinib, have been used for a long time in the treatment of NSCLC. However, they fail to overcome the EGFR-TK mutation due to the acquisition of drug resistance. It is strongly believed that the epithelial-to-mesenchymal transition (EMT) is a key player for acquired resistance and consequent limitation of the clinical efficiency of EGFR-TKIs. Therefore, a new strategy needs to be developed to overcome the resistance in NSCLC. In this current study, we have disclosed for the first time the efficiency of transferrin-modified PLGA-thymoquinone-nanoparticles in combination with gefitinib (NP-dual-1, NP-dual-2 and NP-dual-3) towards gefitinib-resistant A549 cells. The gefitinib-resistant A549 cells (A549/GR) showed 12.3-fold more resistance to gefitinib in comparison to non-resistant A549 cells. The phenotypic alteration resembling spindle-cell shape and increased pseudopodia integuments featured the EMT phenomena in A549/GR cells. EMT in A549/GR was later coupled with the loss of Ecad and expansion of Ncad, along with upregulated vimentin expression, as compared to the control A549 cells. Moreover, the invasive nature and migration potential are more amplified in A549/GR cells. Pre-incubation of A549 cells with TGFß1 also initiated EMT, leading to drug resistance. Conversely, treatment of A549 or A549/GR cells with NP-dual-3 effectively retrieved the sensitivity to gefitinib, restricted the EMT phenomenon, and impaired the TGFß1-induced EMT. On unveiling the underlying mechanism of therapeutic action, we found that STAT3 and miR-21 were individually overexpressed in the A549/GR cells by transfection, and followed by treatment with NP-dual-3. Simultaneously, NP-dual-3 fragmented HIF1-α induced EMT in A549/GR cells and reduced the CSCs markers, viz., Oct-4, Sox-2, Nanog, and Aldh1. These data are self-sufficient to suggest that NP-dual-3 re-sensitizes the drug-resistant A549/GR cells to gefitinib, possibly by retrieving MET phenomena via modulation of STAT3/mir-21/Akt/PTEN/HIF1-α axis. Thus, TQ nanoparticles combined with TKI gefitinib may provide an effective platform to treat NSCLC.

Discovery of a Neutral 40-PdII-Oxo Molecular Disk, [Pd40O24(OH)16{(CH3)2AsO2}16]: Synthesis, Structural Characterization, and Catalytic Studies.

We report on the synthesis and structural characterization of a giant, discrete, and neutral molecular disk, [Pd40O24(OH)16{(CH3)2AsO2}16] (Pd40), comprising a 40-palladium-oxo core that is capped by 16 dimethylarsinate moieties, resulting in a palladium-oxo cluster (POC) with a diameter of ∼2 nm. Pd40, which is the largest known neutral Pd-based oxo cluster, can be isolated either as a discrete species or constituting a 3D H-bonded organic-inorganic framework (HOIF) with a 12-tungstate Keggin ion, [SiW12O40]4- or [GeW12O40]4-. 1H and 13C NMR as well as 1H-DOSY NMR studies indicate that Pd40 is stable in aqueous solution, which is also confirmed by ESI-MS studies. Pd40 was also immobilized on a mesoporous support (SBA15) followed by the generation of size-controlled Pd nanoparticles (diameter ∼2-6 nm, as based on HR-TEM), leading to an effective heterogeneous hydrogenation catalyst for the transformation of various arenes to saturated carbocycles.

Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PLpro.

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are commonly underrepresented in compound libraries that are used for screening in drug discovery campaigns, however, there is growing evidence for their role in medicinal chemistry. Based on previous results, we have selected more than 100 structurally diverse metal complexes for profiling as inhibitors of two relevant SARS-CoV-2 replication mechanisms, namely the interaction of the spike (S) protein with the ACE2 receptor and the papain-like protease PLpro . In addition to many well-established types of mononuclear experimental metallodrugs, the pool of compounds tested was extended to approved metal-based therapeutics such as silver sulfadiazine and thiomersal, as well as polyoxometalates (POMs). Among the mononuclear metal complexes, only a small number of active inhibitors of the S/ACE2 interaction was identified, with titanocene dichloride as the only strong inhibitor. However, among the gold and silver containing complexes many turned out to be very potent inhibitors of PLpro activity. Highly promising activity against both targets was noted for many POMs. Selected complexes were evaluated in antiviral SARS-CoV-2 assays confirming activity for gold complexes with N-heterocyclic carbene (NHC) or dithiocarbamato ligands, a silver NHC complex, titanocene dichloride as well as a POM compound. These studies might provide starting points for the design of metal-based SARS-CoV-2 antiviral agents.

Identification and characterization of mutations in the SARS-CoV-2 RNA-dependent RNA polymerase as a promising antiviral therapeutic target.

The causative agent of COVID-19 is a novel betacoronavirus or severe acute respiratory syndrome coronavirus (SARS-CoV-2), which has emerged as a pandemic of global concern. Considering its rapid transmission, WHO has declared public health emergency on 11th March 2020 worldwide. SARS-CoV-2 is a genetically diverse positive sense RNA virus that typically exhibit high rates of mutation than DNA viruses. Higher rates of mutation bring higher genomic variability which may lead to viral evolution and enabling viruses to evade the pre-existing immunity of host and quickly acquire drug resistance properties. The objective of our study was to compare the SARS-CoV-2 RdRp sequences of Indian SARS-CoV-2 isolates with those of Wuhan type virus. A total of 384 point mutations were detected from 488 sequence of the RdRp protein of Indian SARS-CoV-2 genome, out of which seven were used for subsequent study. Furthermore, prediction of secondary structure, protein modeling and its dynamics were performed which revealed that seven mutations (R118C, T148I, Y149C, E802A, Q822H, V880I and D893Y) significantly altered the stability and flexibility of RdRp protein. Present study was therefore, undertaken to analyze the variations occurring in RdRp due to multiple mutations leading to the alterations in the structure and function of RNA-dependent RNA polymerase which is essential for the replication /transcription of this virus and hence can be utilized as a promising therapeutic target to curb SARS-CoV-2 infections.

Delivery of novel coumarin-dihydropyrimidinone conjugates through mixed polymeric nanoparticles to potentiate therapeutic efficacy against triple-negative breast cancer.

To date, most of the accessible therapeutic options are virtually non-responsive towards triple-negative breast cancer (TNBC) due to its highly aggressive and metastatic nature. Interestingly, chemotherapy reacts soundly in many TNBC cases compared to other types of breast cancer. However, the side effects of many chemotherapeutic agents are still under cross-examination, and thus prohibit their extensive uses. In this present study, we have developed a series of coumarin-dihydropyrimidinone conjugates (CDHPs) and subsequently their poly(lactic-co-glycolic acid) (PLGA)-PEG4000 mixed copolymer nanoparticles as excellent chemotherapeutic nanomedicine to control TNBC. Among all the synthesized CDHPs, CDHP-4 (prepared by the combination of EDCO with 3,4-difluorobenzaldehyde) showed excellent therapeutic effect on a wide variety of cancer cell lines, including TNBC. Besides, it can control the metastasis and stemness property of TNBC. Furthermore, the nano-encapsulation of CDHP-4 in a mixed polymer nanoparticle system (CDHP-4@PP-NPs) and simultaneous delivery showed much improved therapeutic efficacy at a much lower dose, and almost negligible side effects in normal healthy cells or organs. The effectiveness of the present therapeutic agent was observed both in intravenous and oral mode of administration in in vivo experiments. Moreover, on elucidating the molecular mechanism, we found that CDHP-4@PP-NPs could exhibit apoptotic, anti-migratory, as well as anti-stemness activity against TNBC cell lines through the downregulation of miR-138. We validated our findings in MDA-MB-231 xenograft chick embryos, as well as in 4T1-induced mammary tumor-bearing BALB/c mice models, and studied the bio-distribution of CDHP-4@PP-NPs on the basis of the photoluminescence property of nanoparticles. Our recent study, hence for the first time, unravels the synthesis of CDHP-4@PP-NPs and the molecular mechanism behind the anti-migration, anti-stemness and anti-tumor efficacy of the nanoparticles against the TNBC cells through the miR-138/p65/TUSC2 axis.

Arylarsonate- and Phosphonate-Capped Polyoxomolybdates, [(RC6H4As)2Mo6O24]n- and [(R'C6H4P)2Mo5O21]n.

We report on the synthesis and structural characterization of four arylarsonate- and phosphonate-capped polyoxomolybdates that exhibit different organic substituents in the para position of the phenyl group. The reaction of arylarsonates (RAsO3, wherein R = 4-BrC6H4 or 4-N3C6H4) with molybdate in aqueous pH 3.5 media resulted in the cyclic hexamolybdates [(BrC6H4As)2Mo6O24]4- (Mo6As2La) and [(N3C6H4As)2Mo6O24]4- (Mo6As2Lb), whereas the reaction of arylphosphonates (R'PO3, wherein R' = 4-O2CC6H4 or 4-O2CC6H4CH2) with molybdate in aqueous pH 3 media resulted in the cyclic pentamolybdates [(O2CC6H4P)2Mo5O21]6- (Mo5P2Lc) and [(HO2CC6H4CH2P)2Mo5O21]4- (Mo5P2Ld), respectively. Polyanions Mo6As2La and Mo6As2Lb comprise a ring of six MoO6 octahedra that is capped on either side by an organoarsonate group, whereas Mo5P2Lc and Mo5P2Ld consist of a ring of five MoO6 octahedra that is capped on either side by an organophosphonate group, with the organic arms protruding away from the metal-oxo core of the polyanions. All four polyanions Mo6As2La, Mo6As2Lb, Mo5P2Lc, and Mo5P2Ld have been characterized in the solid state by single-crystal X-ray diffraction, IR spectroscopy, and thermogravimetric and elemental analysis and in solution by multinuclear NMR (31P, 13C, and 1H). The synthetic procedure of (4-bromophenyl)arsonic acid, BrC6H4AsO3H2, is reported here for the first time.

Discovery and Supramolecular Interactions of Neutral Palladium-Oxo Clusters Pd16 and Pd24.

We report on the synthesis, structure, and physicochemical characterization of the first three examples of neutral palladium-oxo clusters (POCs). The 16-palladium(II)-oxo cluster [Pd16 O24 (OH)8 ((CH3 )2 As)8 ] (Pd16 ) comprises a cyclic palladium-oxo unit capped by eight dimethylarsinate groups. The chloro-derivative [Pd16 Na2 O26 (OH)3 Cl3 ((CH3 )2 As)8 ] (Pd16 Cl) was also prepared, which forms a highly stable 3D supramolecular lattice via strong intermolecular interactions. The 24-palladium(II)-oxo cluster [Pd24 O44 (OH)8 ((CH3 )2 As)16 ] (Pd24 ) can be considered as a bicapped derivative of Pd16 with a tetra-palladium-oxo unit grafted on either side. The three compounds were fully characterized 1) in the solid state by single-crystal and powder XRD, IR, TGA, and solid-state 1 H and 13 C NMR spectroscopy, 2) in solution by 1 H, 13 C NMR and 1 H DOSY spectroscopic methods, and 3) in the gas phase by electrospray ionization mass spectrometry (ESI-MS).